Peptide Decoding
New?New to peptides?Start here →
Decoding

Beinaglutide_Dosage, benefits & legal status

Also known as benaglutide, rhGLP-1, Feisumei

Published August 24, 2026 · Updated October 5, 2026

China's own GLP-1, and the only one with a fully human sequence.

Blood sugar & weightRecombinant human GLP-1Investigational
DoseSet by the Chinese label
FrequencyThree times daily, before meals
RouteUnder the skin (subcutaneous)
StatusApproved abroad, not FDA approved
CycledSet by the prescription

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

See how this dose compares across the library →

01

What is Beinaglutide?

Plain language first. The technical label stays, but it never stands alone.

Overview

The unmodified human hormone, approved in China. It lasts about eleven minutes, which is why you would inject it three times a day and why every other GLP-1 is chemically altered.

The technical version

Beinaglutide, a recombinant human GLP-1 sharing 100 percent sequence identity with human GLP-1 (7-36), molecular formula C149H225N39O46. Approved by the Chinese regulator in December 2016 for type 2 diabetes and in July 2023 for weight management. Reported half-life approximately 11 minutes, administered three times daily preprandially. Not FDA-approved.

What it's used for

An injected GLP-1 approved in China for type 2 diabetes and for weight management.

02

How does Beinaglutide work?

What it does in the body, and where.

Beinaglutide is the control experiment for the whole GLP-1 class: what happens if you use the real hormone instead of an analog.

  1. 01
    It is the human sequence, unmodified
    Beinaglutide is recombinant human GLP-1 with 100 percent identity to human GLP-1 (7-36). Semaglutide, liraglutide and the rest are deliberately altered to resist breakdown and to bind albumin.
  2. 02
    That is why the dosing is so different
    Its half-life is reported at about 11 minutes, against roughly a week for semaglutide. It is given three times daily, five minutes before meals. The modifications in the analogs are the entire reason weekly dosing exists.
  3. 03
    It is approved in China for both indications
    Approved by the Chinese regulator in December 2016 for type 2 diabetes, and in July 2023 for weight management, where it was the second GLP-1 to gain that indication in China.
  4. 04
    It has a real trial record
    A phase 3 randomized study in Chinese people with overweight or obesity has been published, alongside real-world surveillance covering tens of thousands of patients with type 2 diabetes.
Receptors
HITSGLP-11

Acts on one receptor.

03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Type 2 diabetes, its first approved indication in ChinaClinical use
  • Weight management, approved in China in 2023Clinical use
  • Use in the US, where it is not approvednone

The published record

Research index

57

Papers and trials about Beinaglutide

35 papers tagged human · 20 not reviews or lab · 6 clinical trial publications

8 registered trials · none with posted results

Furthest stage reached: Approved outside the US, China

Compare this against the whole library →

In animals13
In the lab0
Reviews10
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.

Beinaglutide vial rendering
Compound field notes

At a glance

Four things to know about Beinaglutide

01

Evidence

Investigational

02

Category

Weight loss and metabolic

03

Common vial

Varies

04

Half-life

About 11 minutes

04

How much, and do you cycle it?

The range, and whether you take breaks.

Set by the Chinese label, three times daily, before meals. Set by the prescription FDA label

This is a prescription drug. Duration and schedule are set by the label and the prescriber, not by a cycling convention.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

About 11 minutesHuman study

A reported half-life of roughly 11 minutes, which is why it is dosed three times daily rather than weekly. This is the untouched human hormone, and the short half-life is exactly the problem the modified analogs were built to solve.

Not yet traced to a primary source.

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Enter the amount printed on your label.
What you paid per vial
$
Used for cost per dose only.
Your dose (mcg)
Commonly referenced range: 100 up to 200 mcgCommunity practice

Choose your mix

your own mL
units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW0 / 100 units
07

How do you store it?

Before mixing, and after.

Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.

Unmixed lyophilized Beinaglutide keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Solubility, computed: 30% charged residues, 40% hydrophobic. Water usually sufficient.

A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.

Who should avoid it

Check these before anything else.
  • Pregnancy or breastfeeding
  • A personal or family history of medullary thyroid carcinoma, or MEN 2, a class contraindication
  • A history of pancreatitis
  • Use outside a prescription, where no label governs the dose

Stop and get help

These are emergencies. Seek care.
  • Severe or persistent abdominal pain, which can signal pancreatitis
  • Signs of an allergic reaction, including facial or throat swelling or trouble breathing
  • A lump or swelling in the neck, hoarseness, or trouble swallowing

Common effects

Expected, and usually mild.
  • Nausea
  • Dizziness
  • Loss of appetite, which is partly the intended effect
  • Injection site reactions

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is Beinaglutide approved?

And where the numbers on this page come from.

Not in the United States. Beinaglutide has no FDA approval and is in company-run clinical trials, with no legal route to obtain it there outside a trial. It is approved in China.

  • Approval status
    Investigational
  • Route
    Under the skin (subcutaneous)
  • Checked
    22 September 2026
  • Approved outside the US
    China: Approved by China’s regulator in December 2016 for type 2 diabetes, and on 25 July 2023 as Feisumei for weight management. Not approved in the US.This does not change the United States position above.
  • Dose
    From community reports. No regulator or trial established this dose.
  • Vial size
    From what vendors typically list; not a recommendation.
  • Sources
    None traced yet.

What has happened recently

Approved by the Chinese regulator in December 2016 for type 2 diabetes and in July 2023 for weight management. Not approved by the FDA, and not available on prescription in the United States.

Guides for this compound

Sources

No primary source has been traced for this compound yet. Treat everything on this page as unverified until one is. How we grade evidence

Beyond these, 57 records are indexed. Browse the records